{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21","value":"13300"},{"groupId":"OG001","spread":"35","value":"64200"},{"groupId":"OG002","spread":"60","value":"50900"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"comment":"N of 1, no value obtained, no CV value.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"N of 1, Individual data presented, no CV value.","groupId":"OG001","spread":"NA","value":"84100"},{"comment":"CV not available from N=3 for analysis.","groupId":"OG002","spread":"NA","value":"131000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"Cycle 7 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Cohort 1. 100 mg tabalumab (LY2127399) intravenously (IV) on day 1 of each cycle. Bortezomib (BTZ), 1.3 milligram per square meter (mg/m\\^2), IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dexamethasone (Dex), 20 mg/day, on day of and day after BTZ.","id":"OG000","title":"100 mg Tabalumab+BTZ IV+Dex"},{"description":"Cohort 2. 300 mg tabalumab (LY2127399) IV on day 1 of each cycle. BTZ, 1.3 mg/m\\^2, IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dex, 20 mg/day, on day of and day after BTZ IV.","id":"OG001","title":"300 mg Tabalumab+ IV BTZ +Dex"},{"description":"Cohort 2. 300 mg tabalumab (LY2127399) IV on day 1 of each cycle. BTZ, 1.3 mg/m\\^2, IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dex, 20 mg/day, on day of and day after BTZ SC.","id":"OG002","title":"300 mg Tabalumab+ SC BTZ +Dex"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All participants who received at least 1 dose of any study drug and had evaluable PK data. Participants in the 300 mg tabalumab group may have received IV and SC BTZ and may be counted in the IV and SC group for analysis.","reportingStatus":"POSTED","timeFrame":"Cycle 1, Day 1: 6 + or - hours after bortezomib (BTZ); Cycle 7, Day 1: immediately post BTZ dose and 2 hours after tabalumab","title":"Pharmacokinetics (PK): Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-∞) of Tabalumab (LY2127399)","type":"SECONDARY","unitOfMeasure":"ng*hr/mL"}